|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.770 USD | -1.67% |
|
-.--% | -31.92% |
| 07-20 | Nine stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 07-17 | 19 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| Market Cap | 513M 53.82M 46.79M 43.55M 39.98M 75.51M 5.14B 76.68M 201M 2.56B 202M 198M 8.58B | P/E 2026 * |
-1.4x | P/E 2027 * | -2.02x |
|---|---|---|---|---|---|
| Enterprise Value | 408M 42.81M 37.22M 34.64M 31.81M 60.06M 4.09B 60.99M 160M 2.03B 161M 157M 6.82B | EV / Sales 2026 * |
21.5x | EV / Sales 2027 * | 13.5x |
| Free-Float |
70.1% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Orexo AB
| 1 day | -1.67% | ||
| 1 month | -11.50% | ||
| 3 months | -13.45% | ||
| 6 months | -31.92% | ||
| Current year | -31.92% |
| 1 month | 1.36 |  | 2.1 |
| Current year | 1.36 | | 2.65 |
| 1 year | 1.36 | | 4.05 |
| 3 years | 0.89 | | 4.05 |
| 5 years | 0.76 | | 4.13 |
| 10 years | 0.76 | | 9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 54 | 04/02/2013 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 59 | 31/08/2022 |
Jonas Savmarker
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 31/12/2001 | |
George Wilkinson
BRD | Director/Board Member | 70 | 10/04/2019 |
Christine Rankin
BRD | Director/Board Member | 62 | 31/03/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.67% | -.--% | - | - | 53.82M | |
| +0.32% | -0.66% | +64.21% | +23.67% | 322B | |
| +0.21% | +2.87% | +33.60% | -10.34% | 71.6B | |
| -0.91% | +0.74% | +39.85% | +95.22% | 9.79B | |
| -3.60% | -2.43% | -1.16% | -6.92% | 8.39B | |
| +1.80% | -1.99% | -15.78% | -12.22% | 4.3B | |
| -0.68% | -1.87% | -34.78% | +3.04% | 3.81B | |
| +3.08% | -1.41% | -12.94% | +9.52% | 3.58B | |
| -2.15% | -3.40% | +25.70% | +40.83% | 2.59B | |
| +0.85% | +9.88% | -0.25% | -7.32% | 2.25B | |
| Average | -0.28% | -0.34% | +10.94% | +15.05% | 47.54B | |
| Weighted average by Cap. | +0.21% | -0.09% | +54.34% | +18.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 19M 1.99M 1.73M 1.61M 1.48M 2.79M 190M 2.84M 7.46M 94.67M 7.48M 7.32M 317M | 27.5M 2.88M 2.51M 2.33M 2.14M 4.04M 275M 4.11M 10.79M 137M 10.83M 10.59M 459M |
| Net income | -375M -39.32M -34.18M -31.81M -29.21M -55.16M -3.75B -56.01M -147M -1.87B -148M -144M -6.27B | -270M -28.36M -24.65M -22.95M -21.07M -39.79M -2.71B -40.4M -106M -1.35B -107M -104M -4.52B |
| Net Debt | -105M -11.01M -9.57M -8.91M -8.18M -15.44M -1.05B -15.68M -41.21M -523M -41.35M -40.44M -1.75B | -143M -14.99M -13.03M -12.13M -11.14M -21.03M -1.43B -21.36M -56.12M -713M -56.31M -55.07M -2.39B |
Employees
61
Sector
Pharmaceuticals
Calendar
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ORX Stock
- ORXOY Stock
Select your edition
All financial news and data tailored to specific country editions
